<?xml version="1.0" encoding="UTF-8"?>
<p>The Clinical and safety assessment of human Umbilical cord blood‐derived mesenchymal stem cell therapy for RhEumatoid arthritis patients administered intravenously (CURE‐iv) trial is a phase Ia, open‐label, dose‐escalation study for RA patients with a moderate disease activity despite treatment with MTX (
 <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">http://clinicaltrials.gov</ext-link> NCT02221258). The subjects were recruited from the Seoul Metropolitan Government‐Seoul National University Boramae Medical Center. The study was approved by institutional review boards and ethics committees at Korea National Institute for Bioethics Policy, and conducted in accordance with the Good Clinical Practice guidelines and the Declaration of Helsinki. All participants provided written informed consent before the investigation. Patients maintained their regimen of conventional DMARDs and oral corticosteroids (&lt; 10 mg/day of prednisolone or its equivalent) throughout the study period.
</p>
